|Primary analysis complete
|Study Start Date:
|Study Made Public:
A Phase 1 clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost regimens utilizing recombinant adenovirus serotype 35 (rAd35) with HIV-1 clade A Env insert and recombinant adenovirus serotype 5 (rAd5) with HIV-1 clade A or B Env inserts in healthy, HIV-1 uninfected adults
HVTN 083 is a Phase I clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of VRCHIVADV027-00-VP (rAd35), VRCHIVADV038-00-VP (rAd5), and VRCHIVADV052-00-VP (rAd5).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.